This project involves the use of oral Lactobacillus reuteri as an adjunct therapy for 8 weeks. Endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. Intestinal fluid will be collected endoscopically for 16S RNA analysis to assess changes in the gut microbiota. Inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.
Be over 18 years old
Agree to sign informed consent; Have been diagnosed with IBD for at least 3 months but not more than 3 years -
Does not meet the diagnostic criteria of CD
Patients with other autoimmune diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc
Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness
Patients with suspected cancer in their intestines